Adamis Pharmaceuticals and Human Immune Monitoring Center at Stanford University Announce Preliminary Tempol Data in Cells fr...
January 28 2021 - 9:00AM
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) in
collaboration with the Human Immune Monitoring Center at Stanford
University have conducted a study to investigate the effects of
Tempol on immune cells from COVID-19 patients. Preliminary data
from that study shows that Tempol decreases cytokines from
stimulated cells from COVID-19 patients. The collaboration expects
to submit the final data to a peer reviewed journal.
Tempol has previously demonstrated both potent
anti-inflammatory, anticoagulant, and antioxidant activity. Both
inflammatory cytokines and reactive oxygen species (ROS) from cells
of the immune system called macrophages and neutrophils damage the
lung in Acute Respiratory Distress Syndrome (ARDS). In animal
models, Tempol has been shown to decrease proinflammatory cytokines
(cytokine storm), and through its potent antioxidant activity has
been shown to decrease the harmful effects of ROS. In addition,
Tempol has been shown to decrease platelet aggregation, a problem
observed in many COVID-19 patients. Numerous published articles
describing animal models of ARDS show Tempol to cause a decrease in
lung inflammation and preserve lung pathology associated with acute
and chronic lung injury. To this end, Tempol has been shown to
decrease the genes (HIF-la and HIF-2a) associated with hypoxia.
Hypoxia is a key indicator often associated with severe disease and
a poor outcome. Controlling hypoxia and the cytokine storm can be
considered essential to the successful treatment of
COVID-19. Tempol could potentially be used to treat the
many manifestations of COVID-19 and prevent severe disease as well
as the need for hospitalization.
Dr. Dennis J. Carlo, President and CEO of Adamis commented: “We
are very excited about the collaboration with Stanford University.
This is the first data that we know of that shows Tempol has a
positive impact in decreasing cytokine production from COVID-19
positive patient cells. These data further support the need for
clinical studies of Tempol in COVID-19 patients. We intend to
continue pursuing government and/or non-government funding for
these studies; however, the recent exercise of outstanding warrants
have provided the company with additional capital which may be used
to help support and/or accelerate Tempol clinical studies.”
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company primarily focused on developing and
commercializing products in various therapeutic areas, including
allergy, respiratory and inflammatory disease. The company’s
SYMJEPI (epinephrine) Injection products are approved by the FDA
for use in the emergency treatment of acute allergic reactions,
including anaphylaxis. Adamis’ naloxone injection product
candidate, ZIMHI, for the treatment of opioid overdose is currently
under FDA review. Adamis is developing additional products,
including treatments for acute respiratory diseases, such as
COVID-19, influenza, asthma and COPD. The company’s
subsidiary, U.S. Compounding, Inc., compounds sterile
prescription drugs, and certain nonsterile drugs for human and
veterinary use by hospitals, clinics, surgery centers, and vet
clinics throughout most of the United States.
Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include those
that express plans, anticipation, intent, contingencies, goals,
targets or future development and/or otherwise are not statements
of historical fact. These statements relate to future events or
future results of operations, including, but not limited to the
following statements: the company’s beliefs concerning the safety
and effectiveness of Tempol or the company’s other product
candidates; the timing of funding for, or commencement or
completion of, any studies or trials relating to Tempol; the
availability of, and the company’s success in applying for and
obtaining, government or other funding for studies or trials
relating to Tempol or the timing or amount of any such funding; the
results of any future studies or trials that the company may
conduct relating to Tempol; the company’s ability to commercialize
the product candidates described in this press release, itself or
through commercialization partners; and other statements concerning
our future operations and activities. These statements are only
predictions and involve known and unknown risks, uncertainties and
other factors, which may cause Adamis' actual results to be
materially different from the results anticipated by such
forward-looking statements. There can be no assurances regarding
the outcome of our submission of the IND relating to
investigational use of, or trials or studies relating to, Tempol,
regarding the timing or the outcome of any applications or requests
that we may submit for government or other funding for studies or
trials relating to Tempol; concerning the timing or outcome of any
such studies or trials; or that Tempol will be found to be safe and
effective in the treatment of COVID-19 or any other indication. In
addition, forward-looking statements concerning our anticipated
future activities assume that we are able to obtain sufficient
funding to support such activities and continue our operations and
planned activities. As discussed in our filings with
the Securities and Exchange Commission, we will require
additional funding, and there are no assurances that such funding
will be available if required. We cannot assess the impact of each
factor on our business or the extent to which any factor, or
combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements.
You should not place undue reliance on any forward-looking
statements. Further, any forward-looking statement speaks only as
of the date on which it is made, and except as may be required by
applicable law, we undertake no obligation to update or release
publicly the results of any revisions to these forward-looking
statements or to reflect events or circumstances arising after the
date of this press release. Certain of these risks and additional
risks, uncertainties, and other factors are described in greater
detail in Adamis’ filings from time to time with the SEC,
including its annual report on Form 10-K for the year
ended December 31, 2019 and subsequent filings with
the SEC, which Adamis strongly urges you to read and consider,
all of which are available free of charge on
the SEC's web site at http://www.sec.gov. Except to
the extent required by law, any forward-looking statements in this
press release speak only as the date of this press release, and
Adamis expressly disclaims any obligation to update any
forward-looking statements.
Contacts:Mark
FlatherSenior Director, Investor Relations& Corporate
CommunicationsAdamis Pharmaceuticals Corporation(858)
412-7951mflather@adamispharma.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Apr 2023 to Apr 2024